Volume 3, Issue 6, November 2015, Page: 180-183
Optimizing the Effect of ω-3 Fatty Acids on the Lipid Profile in Metabolic Syndrome Patients
Ghada Mahmoud Khafagy, Department of Family Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
Mayssa Ebrahim Ali, Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
Received: Aug. 4, 2015;       Accepted: Aug. 27, 2015;       Published: Nov. 3, 2015
DOI: 10.11648/j.ejpm.20150306.13      View  2567      Downloads  49
Background: The metabolic syndrome is a clustering of metabolic abnormalities and cardiovascular risk factors. It is vital to start the lifestyle interventions and treatment early in patients with metabolic syndrome to prevent the twin global epidemics of type 2diabetes and CVD. Objective: to investigate the overall effects of omega-3 fatty acids supplementation In addition to Dietary Approaches to Stop Hypertension (DASH) nutritional intervention on the lipid profile in patients with metabolic syndrome and to study if the addition of DASH diet will alleviate the rise in LDL- C that occurs with ω-3 fatty acid supplementation. Research design and methods: This was a prospective interventional outpatient trial conducted on 42 patients with the metabolic syndrome. They received ω-3 fatty acid supplementation 1 g/d in addition to DASH nutritional education for 12 weeks: the DASH diet with increased consumption of fruit, vegetables, low-fat dairy and whole grains and lower in saturated fat, total fat, and cholesterol. The main outcome measures were the lipid profile of the patients with metabolic syndrome. Results: ω-3 fatty acid together with The DASH diet significantly changed the mean of all parameters of lipid profile in metabolic syndrome patients. After 12 weeks, there was a significant increase in HDL-C (14%), significant reductions in TG (37.7%), LDL (29.4%) and a significant reduction in Non HDL-C (24.7%). Conclusion: this study demonstrated that the DASH diet optimizes and complements the effect of ω-3 fatty acid on the lipid profile of patients with metabolic syndrome by alleviating the rise in LDL- C that occurs with omega supplementation.
Hypertriglyceridemia, Omega-3 Fatty Acids, LDL, Metabolic Syndrome, DASH, LDL
To cite this article
Ghada Mahmoud Khafagy, Mayssa Ebrahim Ali, Optimizing the Effect of ω-3 Fatty Acids on the Lipid Profile in Metabolic Syndrome Patients, European Journal of Preventive Medicine. Vol. 3, No. 6, 2015, pp. 180-183. doi: 10.11648/j.ejpm.20150306.13
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 285: 2486 –2497, 2001.
Sattar N, Gaw A, Scherbakova O. Metabolic syndrome with and without Creactive protein as a predictor of coronary. Circulation; 108:414-9, 2003.
Praveen S and Mishra S, Early identification prevents type ii diabetes and cardiovascular disease Indian Journal of Clinical Biochemistry; 22 (1): 1-3, 2007.
Young-Hyman D, Schlundt DG, Herman L, De Luca F, Counts D: Evaluation of the insulin resistance syndrome in 5- to 10-year-old overweight/obese African-American children. Diabetes Care; 24: 1359 –1364, 2001.
International Diabetes Federation (IDF) Consensus Worldwide Definition of the Metabolic Syndrome, 2009, available at http://www.idf.org/metabolic-syndrome, last accessed in June 2015.
Varbo A, Benn M, Tybjaerg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol; 61:427-36, 2013.
Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab; 97:2969-89, 2012.
Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol; 51:724-30, 2008.
Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur HeartJ; 32:1345-61, 2011.
Alaupovic P, Mack WJ, Knight-Gibson C, et al. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler Thromb Vasc Biol; 17:715-22, 1997.
George Yuan, Khalid Z. Al-Shali, Robert A. HegeleHypertriglyceridemia: its etiology, effects and treatment. CMAJ; 176(8)1113-1120, 2007.
Karanja NM, Obarzanek E, Lin PH, McCullough ML, Phillips KM, Swain SF, Champagne CM, Hoben KP: Descriptive characteristics of the dietary patterns used in the Dietary Approaches to stop Hypertension trial. J Am Diet Assoc 99(8): S60 –S68, 1999.
Kelley DS, Siegel D, Vemuri M, et al. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr; 86:324–33, 2007.
Bays HE, Tighe AP, Sadovsky R, Davidson MH. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc. Ther. ; 6(3): 391-409. doi:10.1586/14779072.6.3.391, 2008.
Zemel M B., Shi H, Greer B, Dirienzo D And Zemel P C. Regulation of adiposity by dietary calcium. FASEB Journal; 14 (9) 1132-1138, 2000. Doi: 0892-6638/00/0014-1132/$02.25
Yacowitz H, Fleischman AI, Amsden RT. Effects of dietary calcium upon lipid metabolism in rats fed saturated or unsaturated fat. J. Nutr. 92 (3): 389-392, 1967.
Lopes HF, Martin KL, Nashar K, Morrow JD, Goodfriend TL, Egan BM.: DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity.Hypertension 41: 422 –430, 2003.
Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36: 142 –146. doi: 10.1161/01.HYP.36.1.142, 2000.
Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 26: 2261 –2267,. doi:10.2337/diacare.26.8.2261, 2003.
Athyros VG, Karagiannis A, Hatzitolios AI, et al. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin; 25: 971-80, 2009. doi: 10.1185/03007990902810999.
Korantzopoulos P, Elisaf M and Milionis H J. Multifactorial intervention in metabolic syndrome targeting at prevention of chronic kidney disease—ready for prime time? Nephrol Dial Transplant 22: 2768–2774, 2007. doi:10.1093/ndt/gfm525.
Browse journals by subject